Pathway-Based Approaches for Analysis of Genome-Wide Association Studies -A Case Report for Metastatic Small Cell Lung Cancer
JingLu1* ShuQun Cheng2*, Biaoru Li3#
Affiliation
- 1OBGYN, Monterey Park, CA 91754, USA
- 2Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, P.R. China
- 3Georgia Cancer Center, MCG, Augusta, GA, USA 30912
Corresponding Author
Biaoru Li, Department of Pediatrics, Section of Hematology/Oncology, Georgia Cancer Center, MCG, Augusta, GA, USA 30912; E-mail: BLI@gru.edu
Citation
Li, B., et al. Pathway-based Approaches for Genome-Wide Association Studies - A Case Report for Personalized Therapy to Metastatic Small Cell Lung Cancer. (2017) Int J Hematol Ther 3(2): 1- 8.
Copy rights
© 2017 Li, B. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License
Keywords
Abstract
Lung cancer is a common malignant tumor including Small Cell Lung Cancer (SCLC) with 10 - 15 % and Non-Small Cell Lung Cancer (NSCLC) with 70 - 80%. Currently, there are several approaches to be used to treat lung cancer including surgery, chemotherapy, radiation therapy and molecular therapy/immunotherapy, Metastatic SCLC, metastatic mixed type of lung cancer and unclassified lung cancer are still difficult to be cured because this kind of lung cancer is easy to be widely disseminated. For example, if a patient has several metastatic SCLC, the patient will reveal poor outcome. In order to resolve the poor prognosis with recurrent and metastatic SCLC, here we reported a pathway-based approaches for analysis of Genome-Wide Association Studies (GWAS) to screen drugs, hence we used the drugs to treat a patient suffering from SCLC with multiple metastases. In the beginning, we harvested a pair of SCLC cells and normal cells from FFPE samples under laser capture microscopy to achieve the tumor cell DNA for SNP profile. After uncovering SCLC SNP profile, genes related to SNP signature was used to map quantitative network to uncover targeting drugs. Synchronously, the targeting SNPs genes were further confirmed by TaqMan PCR and Sanger’s sequencing. Furthermore, selected drugs were also validated for the SCLC cells by computational modeling. Finally, the drugs approved by FDA were administered for the patient to the personalized therapy. All in all, after the drugs were discovered by GWAS profiles through quantitative network, we successfully achieve a good response for the patient who has suffered from SCLC with multiple metastases